Bruno H Ch Stricker

Erasmus University Rotterdam, Rotterdam, South Holland, Netherlands

Are you Bruno H Ch Stricker?

Claim your profile

Publications (832)

  • Article · Dec 2016
  • Source
    [Show abstract] [Hide abstract] ABSTRACT: Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. Methods: This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Results: Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. Conclusions: This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.
    Full-text Article · Dec 2016 · BMC Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Background: Antimicrobial resistance to ciprofloxacin is rising worldwide, especially in bacteria causing urinary tract infections (UTIs). Prudent use of current antibiotic drugs is therefore necessary. Objectives: We analysed (modifiable) risk factors for ciprofloxacin-resistant Escherichia coli. Methods: Urinary cultures of UTIs caused by E. coli were collected from participants in the Rotterdam Study, a prospective cohort study in an elderly population, and analysed for susceptibility to ciprofloxacin. Multivariate logistic regression was performed to investigate several possible risk factors for resistance. Results: Ciprofloxacin resistance in 1080 E. coli isolates was 10.2%. Multivariate analysis showed that higher age (OR 1.03; 95% CI 1.00-1.05) and use of two (OR 5.89; 95% CI 3.45-10.03) and three or more (OR 3.38; 95% CI 1.92-5.97) prescriptions of fluoroquinolones were associated with ciprofloxacin resistance, while no association between fluoroquinolone use more than 1 year before culture and ciprofloxacin resistance could be demonstrated. Furthermore, a high intake of pork (OR 3.68; 95% CI 1.36-9.99) and chicken (OR 2.72; 95% CI 1.08-6.85) and concomitant prescription of calcium supplements (OR 2.51; 95% CI 1.20-5.22) and proton pump inhibitors (OR 2.04; 95% CI 1.18-3.51) were associated with ciprofloxacin resistance. Conclusions: Ciprofloxacin resistance in community-acquired UTI was associated with a high intake of pork and chicken and with concomitant prescription of calcium supplements and proton pump inhibitors. Modification of antibiotic use in animals as well as temporarily stopping the prescription of concomitant calcium and proton pump inhibitors need further evaluation as strategies to prevent ciprofloxacin resistance.
    Article · Sep 2016 · Journal of Antimicrobial Chemotherapy
  • [Show abstract] [Hide abstract] ABSTRACT: Selective serotonin reuptake inhibitors (SSRIs) are frequently used during pregnancy. Evidence about the long-term consequences of prenatal SSRI exposure on child neurodevelopment is controversial. We prospectively investigated whether prenatal SSRI exposure was associated with childhood non-verbal cognition in a population-based study, and contrasted it to exposure to depressive symptoms (without SSRIs). We included 71 children prenatally exposed to SSRIs, 385 children prenatally exposed to maternal depressive symptoms and 5427 unexposed children. Child executive functioning was assessed by maternal report at 4 years (n=4020). Non-verbal intelligence was measured at 5 years (n=5001) and children were tested with a neuropsychological battery at 7 years (n=1194). Prenatal SSRI exposure was not related to maternal reported executive function at 4 years, nor was it related with observed non-verbal intelligence at age 5 or neuropsychological function at 7 years. Exposure to untreated maternal depressive symptoms was related to maternal reported shifting problems and emotional control problems at 4 years. No associations between exposure to depressive symptoms and observed non-verbal IQ at 5 years or neuropsychological function at 7 years were found. This population-based study suggests that neither SSRI use nor untreated depressive symptoms during pregnancy had a major impact on child non-verbal cognition.
    Article · Sep 2016 · Journal of Psychopharmacology
  • [Show abstract] [Hide abstract] ABSTRACT: Background: In addition to lowering low density lipoprotein cholesterol (LDL-C), statin therapy also raises high density lipoprotein cholesterol (HDL-C) levels. Inter-individual variation in HDL-C response to statins may be partially explained by genetic variation. Methods and results: We performed a meta-analysis of genome-wide association studies (GWAS) to identify variants with an effect on statin-induced high density lipoprotein cholesterol (HDL-C) changes. The 123 most promising signals with p<1×10(-4) from the 16 769 statin-treated participants in the first analysis stage were followed up in an independent group of 10 951 statin-treated individuals, providing a total sample size of 27 720 individuals. The only associations of genome-wide significance (p<5×10(-8)) were between minor alleles at the CETP locus and greater HDL-C response to statin treatment. Conclusions: Based on results from this study that included a relatively large sample size, we suggest that CETP may be the only detectable locus with common genetic variants that influence HDL-C response to statins substantially in individuals of European descent. Although CETP is known to be associated with HDL-C, we provide evidence that this pharmacogenetic effect is independent of its association with baseline HDL-C levels.
    Article · Sep 2016 · Journal of Medical Genetics
  • Source
    [Show abstract] [Hide abstract] ABSTRACT: Background Population-based studies investigating indications for antidepressant prescribing mostly rely on diagnoses from general practitioners. However, diagnostic codes might be incomplete and drugs may be prescribed 'off-label' for indications not investigated in clinical trials. Objective We aimed to study indications for antidepressant use based on self-report. Also, we studied the presence of depressive symptoms associated with the self-reported indications. Setting Our study population of antidepressant users was selected based on interview data between 1997 and 2013 from the prospective population-based Rotterdam Study cohort (age >45 years). Method Antidepressant use, self-reported indication for use, and presence of depressive symptoms (Center for Epidemiological Studies Depression Scale) were based on interview. Self-reported indications were categorized by the researchers into officially approved, clinically-accepted and commonly mentioned off-label indications. Main outcome measures A score of 16 and higher on the Center for Epidemiological Studies Depression Scale was considered as indicator for clinically-relevant depressive symptoms. Results The majority of 914 antidepressant users reported 'depression' (52.4 %) as indication for treatment. Furthermore, anxiety, stress and sleep disorders were reported in selective serotonin reuptake inhibitor and other antidepressant users (ranging from 5.9 to 13.3 %). The indication 'pain' was commonly mentioned by tricyclic antidepressant users (19.0 %). Indications were statistically significantly associated with higher depressive symptom scores when compared to non-users (n = 10,979). Conclusions Depression was the main indication for antidepressant treatment. However, our findings suggest that antidepressants are also used for off-label indications, subthreshold disorders and complex situations, which were all associated with clinically-relevant depressive symptoms in the middle-aged and elderly population.
    Full-text Article · Sep 2016
  • [Show abstract] [Hide abstract] ABSTRACT: Background: To describe patterns of antibiotic outpatient use in three European countries, including two new pediatric-specific quality indicators (QIs). Methods: A cohort study was conducted, 2001-2010, using electronic primary care records of 2,196,312 children up to 14 (Pedianet, Italy) or 18 years (THIN, UK; IPCI, the Netherlands) contributing 12,079,620 person-years. Prevalence rates of antibiotic prescribing per year were calculated and antibiotics accounting (drug utilization) for 90% of all antibiotic prescriptions were identified (DU90% method). The ratio between users of broad to narrow-spectrum penicillins, cephalosporins and macrolides (B/N ratio) and two pediatric-specific quality indicators (QIs): the proportion of amoxicillin users (amoxicillin index, AI) and the ratio between users of amoxicillin to broad-spectrum penicillins, cephalosporins and macrolides (A/B ratio) were determined. Results: The overall annual prevalence of antibiotic prescriptions was 18.0% in the Netherlands, 36.2% in the UK and 52.0% in Italy. Use was maximal in the first years of life. The number of antibiotics accounting for the DU90% was comparable. The B/N ratio varied widely from 0.3 to 74.7. The AI was highest in the Netherlands and the UK (50-60%), lowest in Italy (30%) and worsened over time in the UK and Italy. The A/B ratio in 2010 was 0.3 in Italy, 1.7 in the Netherlands and 5.4 in the UK. Conclusions: The patterns of antibiotic prescribing varied highly with age and country. The pediatric-specific QIs combined with the total prevalence rate of use provide a clear picture of the trends of community childhood antibiotic prescribing, allowing monitoring of the impact of policy interventions.
    Article · Sep 2016 · The Pediatric Infectious Disease Journal
  • Source
    [Show abstract] [Hide abstract] ABSTRACT: Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear. Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome-wide association study (GWAS), consisting of 13,123 participants of different ancestries. The C allele of rs8192675 in the intron of SLC2A2, which encodes the facilitated glucose transporter GLUT2, was associated with a 0.17% (P = 6.6 × 10(-14)) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry. rs8192675 was the top cis expression quantitative trait locus (cis-eQTL) for SLC2A2 in 1,226 human liver samples, suggesting a key role for hepatic GLUT2 in regulation of metformin action. Among obese individuals, C-allele homozygotes at rs8192675 had a 0.33% (3.6 mmol/mol) greater absolute HbA1c reduction than T-allele homozygotes. This was about half the effect seen with the addition of a DPP-4 inhibitor, and equated to a dose difference of 550 mg of metformin, suggesting rs8192675 as a potential biomarker for stratified medicine.
    Full-text Article · Aug 2016 · Nature Genetics
  • [Show abstract] [Hide abstract] ABSTRACT: Objective: Selective serotonin reuptake inhibitors (SSRIs) may decrease insulin secretion, but evidence from population studies is scarce. We investigated the association between SSRIs and markers for glucose-insulin homeostasis in a nondiabetic older population. Furthermore, we studied the association between SSRI use and insulin dependence in a diabetic population of older adults. Methods: This study was embedded in the prospective population-based Rotterdam Study cohort (1991-2012). In nondiabetic participants, fasting glucose and insulin levels and the homeostasis model assessment for insulin sensitivity and secretion were compared between participants using SSRIs and participants using no antidepressant. In diabetic patients using oral glucose-lowering agents, the risk of insulin dependence, defined as the start of insulin treatment, was compared between participants using SSRIs and participants using no antidepressant. Results: In nondiabetic participants, SSRI users (n = 87) had, compared with participants using no antidepressants (n = 5,505), a significantly (P < .05) lower level of insulin (8.8 mU/L and 9.9 mU/L, respectively), a lower degree of insulin resistance (2.2% and 2.4%, respectively), and less insulin secretion (89.1% and 100.4%, respectively), but a similar glucose level. Furthermore, > 90 days of consecutive use of SSRIs in diabetic patients was associated with a 2.17 times higher risk (95% confidence interval, 1.02-4.60) of starting insulin treatment than that of participants using no antidepressants. Conclusions: Use of SSRIs was associated with lower insulin secretion in nondiabetic participants and an increased risk of insulin dependence in type 2 diabetics in older adults. However, additional studies are required to confirm our results.
    Article · Aug 2016 · The Journal of Clinical Psychiatry
  • Source
    [Show abstract] [Hide abstract] ABSTRACT: The implantation of cardiac pacemakers has become a well-established therapy for conduction disorders and sinus node dysfunction. In many countries pacemaker registries have been initiated in order to collect information on patient characteristics, trends in numbers and the types of pacemakers used, to identify problematic devices, and for safety monitoring. For this utilisation study the Central Pacemaker Patients Registration (CPPR) from the Netherlands Pacemaker Registry Foundation (CPPR-SPRN) containing data collected for more than 20 years was used. During this period nearly 97,000 first pacemakers were implanted. Analyses show an increase in the rate of implanted devices. The change in pacemaker type from VVI to DDD, followed by biventricular stimulation, is reflected by the number of simultaneously implanted leads, which is partly a consequence of cardiac resynchronisation therapy. Our data demonstrate that indications for implantation and type of pacemaker are comparable with other European countries.
    Full-text Article · Aug 2016 · Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
  • Martina Teichert · Eugene van Puijenbroek · Bruno H. Stricker
    [Show abstract] [Hide abstract] ABSTRACT: Contraindicated use in women; Off label use; Concomitant contraception; Medication surveillance update; Teratogenicity
    Article · Aug 2016 · British Journal of Clinical Pharmacology
  • [Show abstract] [Hide abstract] ABSTRACT: Context: Except from associations study with body weight, there are few longitudinal data regarding the association between thyroid function and anthropometric such as waist circumference, waist-to-hip-ratio or waist-to height-ratio. Objective: We aimed at investigating the association of thyroid stimulating hormone (TSH) at baseline with changes in different anthropometric markers between baseline and follow-up in the general population. Design and setting: We used data from four population-based longitudinal cohort studies and one population-based cross-sectional study. Subjects: We studied 16,902 (8,204 males and 8,698 females) subjects aged 20 to 95 years from the general population. Main outcome measures: We measured body mass index, waist-circumference, waist-to-hip- ratio and waist-to-height-ratio. Multivariable median regression models were calculated adjusting for the following covariates: age, sex, baseline value of the respective anthropometric marker, smoking status, follow-up-time period and study site. Results: In cross-sectional analyses, serum TSH within the reference range was positively associated with waist circumference (β 0.94 cm (95%CL 0.56; 1.32)) and waist-to-height-ratio (β 0.029 (95%CL 0.017; 0.042)). These associations were also present for the full range of TSH. In the longitudinal analyses, serum TSH at baseline was inversely associated with 5-year change of all considered anthropometric measures within the prior defined study-specific reference range, as well as in the full range of serum TSH. Conclusion: High TSH serum levels were positively associated with current anthropometric markers even in the study-specific reference ranges. In contrast, high TSH serum levels were associated with decreased anthropometric markers over a time span of approximately 5 years. Further research is needed to determine possible clinical implications as well as public health consequences of these findings.
    Article · Jul 2016 · Thyroid
  • [Show abstract] [Hide abstract] ABSTRACT: Importance The American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC) guidelines both recommend lipid-lowering treatment for primary prevention based on global risk for cardiovascular disease (CVD). However, randomized clinical trials (RCTs) for statin use have included participants with specific risk-factor profiles. Objective To evaluate the overlap between the ACC/AHA and ESC guideline recommendations and available evidence from RCTs for statin use in primary prevention of CVD. Design, Setting, and Participants We calculated the 10-year risk for hard atherosclerotic CVD (ASCVD) following the ACC/AHA guideline, 10-year risk of CVD mortality following the ESC guideline, and we determined eligibility for each of 10 major RCTs for primary prevention of CVD. Conducted from July 2014 to August 2015, this study included 7279 individuals free of CVD, aged 45 to 75 years, examined between 1997 and 2008 for the Rotterdam Study, a prospective population-based cohort. Main Outcomes and Measures Proportions of individuals qualifying for lipid-lowering treatment per guidelines, proportions of individuals eligible for any of the 10 RCTs, overlap between these groups, and corresponding ASCVD incidence rates. Results Of the 7279 individuals included in the study, 58.2% were women (n = 4238) and had a mean (SD) age of 61.1 (6.9) years. The ACC/AHA guidelines would recommend statin initiation in 4284 participants (58.9%), while the ESC guidelines would in 2399 participants (33.0%) (overlapping by 95.8% with ACC/AHA). A total of 3857 participants (53.0%) met eligibility criteria for at least 1 RCT. Recommendations from both guidelines and trial evidence overlapped for 1546 participants (21.2%), who were at high risk for ASCVD (21.5 per 1000 person-years). A further 1703 participants (23.4%) would be recommended for statins by the guidelines in the absence of direct trial evidence, while 1176 (16.2%) would have been eligible for at least 1 trial without being recommended statin treatment by any guideline. Finally, 1719 participants (23.6%) would not be recommended a statin, nor would qualify for any of the trials. These individuals had low incidence of ASCVD (3.3 per 1000 person-years). Conclusions and Relevance Based on this European population study, ACC/AHA and ESC prevention guidelines often did not align at the individual level. However, for one-fifth of the general population, guidelines on both sides of the Atlantic recommend statin initiation, with trial data supporting the efficacy. There should be no controversy about providing optimal preventive medication to these individuals.
    Article · Jul 2016 · JAMA Cardiology
  • [Show abstract] [Hide abstract] ABSTRACT: Background Early identification of individuals at high risk of developing neurodegenerative diseases is essential for timely preventive intervention. However, simple methods that can be used for risk assessment in general practice are lacking. Methods Within the population-based Rotterdam Study, we used the Purdue Pegboard Test (PPT) to assess manual dexterity in 4,856 persons (median age 70 years, 58% women) free of parkinsonism and dementia between 2000 and 2004. We followed these persons until January 1, 2012 for the onset of neurodegenerative diseases (defined as first diagnosis of parkinsonism or dementia). We determined the association of PPT scores with incident neurodegenerative disease, adjusting for age, sex, study cohort, level of education, smoking, preferred hand, parental history, memory complaints, and Mini-Mental State Examination. Furthermore, we determined the incremental predictive value of PPT, expressed as change in risk classification and discrimination. Results During follow-up (median 9.2 years), 277 participants were diagnosed with a neurodegenerative disease (227 with dementia and 50 with parkinsonism). Lower PPT scores were associated with higher risk of incident neurodegenerative diseases (hazard ratio [HR] = 1.28, 95% confidence interval [CI]: 1.18–1.41) and improved discrimination of incident neurodegenerative diseases. We also observed significant associations of PPT scores separately with incident dementia (HR = 1.25; 95% CI: 1.14–1.39]) and incident parkinsonism (HR = 1.41; 95% CI: 1.19–1.67). Conclusions A rapid, nonlaboratory test of manual dexterity may help to identify persons at high risk for neurodegenerative diseases. This highlights the importance of motor function in the preclinical phase of both dementia and parkinsonism and may aid in selecting individuals for refined screening and neuroprotective trials.
    Article · Jul 2016 · The Journals of Gerontology Series A Biological Sciences and Medical Sciences
  • Brenda C.T. Kieboom · Bruno H. Stricker
    Article · Jul 2016
  • Article · Jul 2016 · Journal of Thoracic Disease
  • Article · Jul 2016 · Journal of Thoracic Disease
  • Raymond Noordam · Christy L Avery · Loes E Visser · Bruno H Stricker
    [Show abstract] [Hide abstract] ABSTRACT: Antidepressants are often only moderately successful in decreasing the severity of depressive symptoms. In part, antidepressant treatment response in patients with depression is genetically determined. However, although a large number of studies have been conducted aiming to identify genetic variants associated with antidepressant drug response in depression, only a few variants have been repeatedly identified. Within the present review, we will discuss the methodological challenges and limitations of the studies that have been conducted on this topic to date (e.g., 'treated-only design', statistical power) and we will discuss how specifically drug-gene interaction models can be used to be better able to identify genetic variants associated with antidepressant drug response in depression.
    Article · Jun 2016 · Pharmacogenomics
  • Source
    [Show abstract] [Hide abstract] ABSTRACT: Data S1. Methods. Table S1. Hazard Ratios (95% CIs) of Carotid Intima‐Media Thickness for Atrial Fibrillation Adjusted for Hospitalization: ARIC and MESA Table S2. C‐Statistic, Categorical‐Based NRI, and Relative IDI for Atrial Fibrillation When Each Arterial Index Is Added to the Refitted CHARGE‐AF Model in Participants Without Heart Failure or Myocardial Infarction: ARIC, MESA, and RS Table S3. C‐Statistic, Categorical‐Based NRI, and Relative IDI for Atrial Fibrillation When Each Arterial Index Is Added to the Refitted CHARGE‐AF Model in Participants With BMI <30 kg/m2: ARIC, MESA, and RS Table S4. C‐Statistic, Categorical‐Based NRI, and Relative IDI for Atrial Fibrillation When Each Arterial Index Is Added to the Refitted CHARGE‐AF Model in Participants With BMI ≥30 kg/m2: ARIC, MESA, and RS
    Full-text Dataset · May 2016
  • Source
    Dataset: S1 Text
    [Show abstract] [Hide abstract] ABSTRACT: Supplementary Materials, Methods and Results. (DOCX)
    Full-text Dataset · May 2016

Publication Stats

24k Citations

Institutions

  • 1993-2016
    • Erasmus University Rotterdam
      • • Department of Medical Informatics
      • • Department of Internal Medicine
      Rotterdam, South Holland, Netherlands
  • 2001-2015
    • Erasmus MC
      • Department of Epidemiology
      Rotterdam, South Holland, Netherlands
  • 2014
    • University Medical Center Utrecht
      Utrecht, Utrecht, Netherlands
  • 2009
    • Universitair Ziekenhuis Ghent
      Gand, Flanders, Belgium
  • 1995-2009
    • Universiteit Utrecht
      • • Utrecht Institute for Pharmaceutical Sciences
      • • Division of Pharmacoepidemiology and Pharmacotherapy
      Utrecht, Utrecht, Netherlands
  • 2007
    • Harvard University
      Cambridge, Massachusetts, United States
    • Massachusetts General Hospital
      Boston, Massachusetts, United States
  • 2004-2007
    • Radboud University Nijmegen
      Nymegen, Gelderland, Netherlands
  • 1992-2006
    • University of Groningen
      • Department of Clinical Pharmacology
      Groningen, Groningen, Netherlands
  • 1996
    • Diergaarde Blijdorp
      Rotterdam, South Holland, Netherlands
    • Medisch Spectrum Twente
      • Hospital Medical Spectrum Twente
      Enschede, Overijssel, Netherlands